stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
30.70
0.56
+1.86%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) EPS (diluted)
Vera Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$4.66, compared with −$2.75 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$5.86. Over the past ten years it has ranged from −$166.93 (fiscal 2020) to −$2.25 (fiscal 2023); the current reading is higher than 43% of that period. Vera Therapeutics, Inc. ranks 459th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$4.66 | — |
| FY2024 | −$2.75 | — |
| FY2023 | −$2.25 | — |
| FY2022 | −$3.35 | — |
| FY2021 | −$2.43 | — |
| FY2020 | −$166.93 | — |
| FY2019 | −$40.13 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.52 | — |
| Mar 2026 | −$1.69 | — |
| Dec 2025 | −$1.39 | — |
| Sep 2025 | −$1.26 | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$166.93
High −$2.25
Ten-year median
−$3.35
Current reading's percentile
43
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| IMNM Immunome, Inc. compare | −$2.53 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item